Last reviewed · How we verify
Tigan®
Tigan (trimethobenzamide) blocks dopamine receptors in the chemoreceptor trigger zone to prevent nausea and vomiting.
Tigan (trimethobenzamide) blocks dopamine receptors in the chemoreceptor trigger zone to prevent nausea and vomiting. Used for Nausea and vomiting, Postoperative nausea and vomiting.
At a glance
| Generic name | Tigan® |
|---|---|
| Sponsor | Ipsen |
| Drug class | Dopamine antagonist antiemetic |
| Target | Dopamine receptor (D2) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology / Antiemetic |
| Phase | FDA-approved |
Mechanism of action
Trimethobenzamide is an antiemetic that acts as a dopamine antagonist, primarily affecting the chemoreceptor trigger zone in the brain. By blocking dopamine receptors in this area, it suppresses the vomiting reflex and reduces nausea. It has weaker antihistamine and anticholinergic properties compared to other antiemetics.
Approved indications
- Nausea and vomiting
- Postoperative nausea and vomiting
Common side effects
- Drowsiness
- Headache
- Diarrhea
- Muscle cramps
- Hypotension
Key clinical trials
- Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT) (PHASE4)
- Safety/Efficacy of Tigan® to Control Nausea/Vomiting Experienced During Apokyn® Initiation and Treatment (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |